BRAF and melanoma: To evaluate the usefulness of CTCs as biomarkers of responsiveness to treatment, we next analyzed blood from five patients with BRAF-mutated melanoma (MMbraf1–5), who were treated with BRAF/MEK inhibitors (Table S1).